| Similar Articles |
|---|
 |
The Motley Fool
April 8, 2004
Charly Travers |
Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.   |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 3, 2004
Charly Travers |
New Chapter for Indevus The drug company Indevus puts troubled history behind it with the launch of the drug Sanctura which is now on the market for the treatment of overactive bladder. |
The Motley Fool
December 14, 2004
Charly Travers |
A Stagnant Drug Stock A drug launch is not driving share price increases for Indevus. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
The Motley Fool
September 29, 2008
Brian Orelli |
An Overnight 2-Bagger A nod from the FDA and a new partnership boost Indevus shares. Where to, now? |
The Motley Fool
August 17, 2007
Brian Orelli |
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
May 3, 2013
Phillip Broadwith |
Judge reverses jury decision over $6.5m Takeda payout A judge has thrown out the jury's verdict in a case between Japanese drugmaker Takeda and a US man who claims that the company's drug caused his bladder cancer. |
